Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351825 | 0.84 | PARK7 (0.48) | PARK7KDM4EALDH1A1BRD4BRPF1 | |
| Trifluoroacetic Acid SCHEMBL353832 | 0.80 | PARK7 (0.45) | PARK7MAPTTSHRKDM4EALDH1A1 | |
| SCHEMBL16649963 | 0.76 | PARK7 (0.42) | PARK7MAPTKDM4EALDH1A1 | |
| SCHEMBL351909 | 0.73 | PARK7 (0.43) | PARK7 | |
| SCHEMBL354624 | 0.72 | PARK7 (0.41) | PARK7MAPTKDM4EALDH1A1 | |
| SCHEMBL353833 | 0.69 | BRD4 (0.38) | PARK7MAPTTSHRALDH1A1BRD4 | |
| SCHEMBL16649823 | 0.68 | PARK7 (0.48) | PARK7MAPTTSHRKDM4EALDH1A1 | |
| SCHEMBL352312 | 0.68 | PARK7 (0.55) | PARK7MAPTKDM4EALDH1A1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1669417 | 0.68 | PARK7 (0.54) | PARK7MAPTTSHRKDM4EALDH1A1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14491796 | 0.68 | PARK7 (0.54) | PARK7MAPTTSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | claimed |
| EP-2411376-A1 | INHIBITORS OF NF-KB | Profectus Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | NFKBIA, IKBKB, IKBKG | PARK7 3327/4885MAPT 2761/4885TSHR 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.